Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Inventory (2016 - 2025)

Historic Inventory for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $321.2 million.

  • Haemonetics' Inventory rose 131660.98% to $321.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $321.2 million, marking a year-over-year increase of 131660.98%. This contributed to the annual value of $365.1 million for FY2025, which is 1511.31% up from last year.
  • Per Haemonetics' latest filing, its Inventory stood at $321.2 million for Q4 2025, which was up 131660.98% from $336.2 million recorded in Q3 2025.
  • Haemonetics' 5-year Inventory high stood at $382.1 million for Q3 2024, and its period low was -$26.4 million during Q4 2024.
  • For the 5-year period, Haemonetics' Inventory averaged around $296.4 million, with its median value being $311.5 million (2022).
  • Per our database at Business Quant, Haemonetics' Inventory plummeted by 10868.35% in 2024 and then surged by 131660.98% in 2025.
  • Quarter analysis of 5 years shows Haemonetics' Inventory stood at $322.7 million in 2021, then decreased by 20.74% to $255.8 million in 2022, then grew by 18.87% to $304.0 million in 2023, then plummeted by 108.68% to -$26.4 million in 2024, then skyrocketed by 1316.61% to $321.2 million in 2025.
  • Its Inventory was $321.2 million in Q4 2025, compared to $336.2 million in Q3 2025 and $360.5 million in Q2 2025.